BackInozyme Pharma Overview

Inozyme Pharma Current Cash

Track Inozyme Pharma's current cash ($26M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$25.85M
↑ 25.36% YoYΔ $5.23M vs prior year quarter

Peer trimmed avg / median

Loading

Inozyme Pharma Current Cash History

Loading

Inozyme Pharma vs. peers: Current Cash Comparison

Loading

Inozyme Pharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Inozyme Pharma (INZY) FAQ

Inozyme Pharma (INZY) currently reports a current cash of $26M as of March 2025. That compares with $21M in the prior-year period — up 25.4% year over year. Use the charts on this page to explore Inozyme Pharma's current cash history and peer comparisons.

Inozyme Pharma's current cash increased from $21M to $26M — a 25.4% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Inozyme Pharma reported $26M in current cash as of March 2025. That compares with $21M in the prior-year period — up 25.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $26M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Inozyme Pharma, and consider following INZY for alerts when major investors trade the stock.

Inozyme Pharma is classified in the Healthcare sector. On current cash, it currently shows $26M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INZY with unrelated industries.